<DOC>
	<DOCNO>NCT02251717</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) 12 24 week adults chronic genotype 1 genotype 4 hepatitis C virus ( HCV ) infection kidney transplant .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir ( LDV/SOF ) Fixed Dose Combination ( FDC ) 12 24 Weeks Kidney Transplant Recipients With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Genotype 1 4 chronic HCV infection Have receive kidney transplant 6 month Baseline visit Cirrhosis determination Screening laboratory parameter within defined threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol Planned anticipated second kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>renal transplant</keyword>
</DOC>